Article offers guidance on discussing PSA with patients

Article offers guidance on discussing PSA with patients

(HealthDay)—Discussion of prostate-specific antigen (PSA) screening should focus on current guidelines and emphasize shared decision making, according to an article published Feb. 11 in the Urology Times.

Noting that there has been an increase in discourse relating to the controversy surrounding PSA testing in the lay press, John M. Hollingsworth, M.D., from the University of Michigan Medical School in Ann Arbor, outlined his patient discussions concerning PSA screening.

The author notes that most concerns relating to PSA testing stem from the current American Academy of Family Physicians and U.S. Preventive Services Task Force guidelines against PSA screening. However, other organizations, including the American College of Physicians (ACP), American Cancer Society, and American Urological Association (AUA), recommend that patients and physicians consider the benefits and harms of PSA screening. The ACP recommends PSA testing for men with a clear preference for screening aged 50 to 69 years, while the AUA recommends it for those aged 55 to 69 years. Decision aids have been developed to assist with the process of shared between the patient and physician; these may be useful in discussions with patients.

"During the initial consultation with a patient, it is also important to discuss the uncertainties, risks, and potential benefits of PSA screening so that he can make an informed decision," Hollingsworth writes. "Subsequent decisions on continued PSA must take into account changes to a man's health and preferences."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Men say they want prostate cancer test, despite risks

Jul 09, 2013

A survey of men age 40 to 74 found that 54 percent said that they would still opt for a popular prostate cancer screening test despite recent recommendations that the test not be performed, finds a new study ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.